Country-based report: the safety of omalizumab treatment in pregnant patients with asthma

Bilun GEMİCİOĞLU, (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İstanbul, Türkiye)
Arzu Didem YALÇIN, (Sağlık Bilimleri Üniversitesi, Antalya Eğitim ve Araştırma Hastanesi, Alerji ve İmmünoloji Anabilim Dalı, İç Hastalıkları Anabilim Dalı, Antalya, Türkiye)
Yavuz HAVLUCU, (Celal Bayar Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Manisa, Türkiye)
Gül KARAKAYA, (Hacettepe Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İmmünoloji ve Allerji Anabilim Dalı, Ankara, Türkiye)
Levent ÖZDEMİR, (Dörtyol Devlet Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Adana, Türkiye)
Metin KEREN, (Süreyyapaşa Göğüs Hastalıkları Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, İstanbul, Türkiye)
Sevim BAVBEK, (Ankara Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Alerji ve Klinik İmmünoloji Anabilim Dalı, Ankara Türkiye)
Dane EDİGER, (Uludağ Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Bursa, Türkiye)
İ.Kıvılcım OĞUZÜLGEN, (Gazi Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Zeynep FERHAN OZSEKER, (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, İstanbul, Türkiye)
Ayşe Arzu YORGANCIOĞLU,
Turkish Journal of Medical Sciences
4 2
Yıl: 2021 Cilt: 51 Sayı: 5 Sayfa Aralığı: 2516 - 2523 Metin Dili: İngilizce DOI: 10.3906/sag-2101-341 İndeks Tarihi: 07-01-2022

Country-based report: the safety of omalizumab treatment in pregnant patients with asthma

Öz:
Background/aim: We aimed to report outcomes of pregnant patients with asthma under omalizumab treatment and their infants in our country. Materials and methods: Patients with asthma who received omalizumab for at least 6 months and at least one dose during their pregnancy were retrospectively evaluated using a questionnaire regarding their disease and therapy and the health of their infants. Results: Twenty pregnant patients and their 23 infant’s data were analyzed. The mean delivery age was 31.8 ± 7.4 years. They received omalizumab for 28.9 ± 21.8 months. Eight (36.4%) patients showed exacerbation of the disease during pregnancy. Forced expiratory volume in 1 s (FEV1) and asthma control test (ACT) scores at the starting time of omalizumab administration, first month of the pregnancy, and after delivery were 71 ± 18%, 83.4 ± 10.5%, and 80.5 ± 13% (FEV1), and 11.9 ± 4.9, 20.2 ± 2.6, and 20.4 ± 2.2 (ACT), respectively. One patient gave birth to twin infants, two patients to two infants each in different years, and 17 to one infant each. Three (13%) infants had low birth weight and five (21.7%) were born prematurely. No congenital anomalies were detected. Seven (30.4%) infants presented atopic diseases during their life. Conclusion: Omalizumab treatment during pregnancy seems to be safe for both patients and their infants.Key words: Exacerbation, gestation, infant, omalizumab, pregnancy, prematurity
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. Journal of Allergy and Clinical Immunology 2017; 139 (2): 438-447. doi: 10.1016/j.jaci.2016.06.054
  • 2. Yildiz F, Oguzulgen IK, Dursun B, Mungan D, Gemicioglu B et al. Turkish Thoracic Society asthma management and prevention guideline: key points. Tuberculosis and Thorax 2011; 59: 291-311. doi: 10.5578/tt.2750
  • 3. Maselli DJ, Adams SG, Peters JI, Levine SM. Management of asthma during pregnancy. Therapeutic Advances in Respiratory Disease 2013; 7 (2): 87-100. doi: 10.1177/1753465812464287
  • 4. Murphy VE. Managing asthma in pregnancy. Breathe 2015; 11 (4): 258-267. doi: 10.1183/20734735.007915
  • 5. Bonham CA, Patterson KC, Strek ME. Asthma outcomes and management during pregnancy. Chest 2018; 153 (2): 515-527. doi: 10.1016/j.chest.2017.08.029
  • 6. Namazy J, Cabana MD, Scheuerle AE, Thorp JM Jr, Chen H et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. Journal of Allergy and Clinical Immunology 2015; 135 (2): 407-412. doi: 10.1016/j. jaci.2014.08.025
  • 7. Pfaller B, Yepes-Nuñez JJ, Agache I, Akdis CA, Alsalamah M et al. Biologicals in atopic disease in pregnancy: an EAACI position paper. Allergy 2021; 76 (1): 71-89. doi: 10.1111/ all.14282
  • 8. Yorgancıoğlu A, Öner Erkekol F, Mungan D, Erdinç M, Gemicioğlu B et al. Long-term omalizumab treatment: a multicenter, real-life, 5-year trial. International Archives of Allergy and Immunology 2018; 176 (3-4): 225-233. doi: 10.1159/000488349
  • 9. Yilmaz I, Erkekol FO, Celen S, Karaca MZ, Aydin Ö et al. Does drug compliance change in asthmatic patients during pregnancy. Multidisciplinary Respiratory Medicine 2013; 8 (1): 38. doi: 10.1186/2049-6958-8-38
  • 10. Mendola P, Wallace M, Hwang BS, Liu D, Robledo C et al. Preterm birth and air pollution: Critical windows of exposure for women with asthma. Journal of Allergy and Clinical Immunology 2016; 138 (2): 432-440.e5. doi: 10.1016/j. jaci.2015.12.1309
  • 11. Azad MB, Moyce BL, Guillemette L, Pascoe CD, Wicklow B et al. Diabetes in pregnancy and lung health in offspring: developmental origins of respiratory disease. Paediatric Respiratory Reviews 2017; 21: 19-26. doi: 10.1016/j. prrv.2016.08.007
  • 12. Schatz M, Dombrowski M, Wise R, Thom E, Landon M et al. Asthma morbidity during pregnancy can be predicted by severity classification. Journal of Allergy and Clinical Immunology 2003; 112: 283–288. doi: 10.1067/mai.2003.1516
  • 13. Murphy V, Gibson P. Asthma in pregnancy. Clinical Chest Medicine 2011; 32: 93–110. doi: 10.1016/j.ccm.2010.10.001
  • 14. Bonham CA, Patterson KC, Strek ME. Asthma Outcomes and Management During Pregnancy. Chest 2018; 153 (2): 515-527. doi: 10.1016/j.chest.2017.08.029
  • 15. Fazel N, Kundi M, Jensen-Jarolim E, Pali-Schöll I, Kazemzadeh A et al. Prospective cohort study of pregnancy complications and birth outcomes in women with asthma. Archives of Gynecology and Obstetrics. 2018; 298 (2): 279-287. doi: 10.1007/s00404-018-4800-y
  • 16. Palmsten K, Schatz M, Chan PH, Johnson DL, Chambers CD. Validation of the Pregnancy Asthma Control Test. Journal of Allergy and Clinical Immunology in Practice 2016; 4 (2): 310- 305.e1. doi: 10.1016/j.jaip.2015.11.019
  • 17. de Araujo GV, Leite DF, Rizzo JA, Sarinho ES. Asthma in pregnancy: association between the Asthma Control Test and the Global Initiative for Asthma classification and comparisons with spirometry. European Journal of Obstetrics & Gynecology and Reproductive Biology 2016; 203: 25-29. doi: 10.1016/j. ejogrb.2016.05.010
  • 18. Blais L, Forget A. Asthma exacerbations during the first trimester of pregnancy and the risk of congenital malformations among asthmatic women. Journal of Allergy and Clinical Immunology 2008; 121: 1379–1384. doi: 10.1016/j.jaci.2008.02.038
  • 19. Murphy V, Namazy J, Powell H, Schatz M, Chambers C, Attia J. A meta-analysis of adverse perinatal outcomes in women with asthma. BJOG: International Journal of Obstetrics & Gynaecology 2011; 118: 1314–1323. doi: 10.1111/j.1471- 0528.2011.03055.x
  • 20. Clift V, Giles W, Smith R, Bisits A, Hempenstall P, Kessell C. Alterations of placental vascular function in asthmatic pregnancies. American Journal of Respiratory and Critical Care Medicine 2001; 164: 546–553. doi: 10.1164/ ajrccm.164.4.2009119
APA Gemicioglu B, YALÇIN A, HAVLUCU Y, KARAKAYA G, Özdemir L, KEREN M, Bavbek S, Ediger D, Oguzulgen I, OZSEKER Z, yorgancıoglu a (2021). Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. , 2516 - 2523. 10.3906/sag-2101-341
Chicago Gemicioglu Bilun,YALÇIN Arzu Didem,HAVLUCU YAVUZ,KARAKAYA GÜL,Özdemir Levent,KEREN METİN,Bavbek Sevim,Ediger Dane,Oguzulgen I.Kivilcim,OZSEKER ZEYNEP FERHAN,yorgancıoglu arzu Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. (2021): 2516 - 2523. 10.3906/sag-2101-341
MLA Gemicioglu Bilun,YALÇIN Arzu Didem,HAVLUCU YAVUZ,KARAKAYA GÜL,Özdemir Levent,KEREN METİN,Bavbek Sevim,Ediger Dane,Oguzulgen I.Kivilcim,OZSEKER ZEYNEP FERHAN,yorgancıoglu arzu Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. , 2021, ss.2516 - 2523. 10.3906/sag-2101-341
AMA Gemicioglu B,YALÇIN A,HAVLUCU Y,KARAKAYA G,Özdemir L,KEREN M,Bavbek S,Ediger D,Oguzulgen I,OZSEKER Z,yorgancıoglu a Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. . 2021; 2516 - 2523. 10.3906/sag-2101-341
Vancouver Gemicioglu B,YALÇIN A,HAVLUCU Y,KARAKAYA G,Özdemir L,KEREN M,Bavbek S,Ediger D,Oguzulgen I,OZSEKER Z,yorgancıoglu a Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. . 2021; 2516 - 2523. 10.3906/sag-2101-341
IEEE Gemicioglu B,YALÇIN A,HAVLUCU Y,KARAKAYA G,Özdemir L,KEREN M,Bavbek S,Ediger D,Oguzulgen I,OZSEKER Z,yorgancıoglu a "Country-based report: the safety of omalizumab treatment in pregnant patients with asthma." , ss.2516 - 2523, 2021. 10.3906/sag-2101-341
ISNAD Gemicioglu, Bilun vd. "Country-based report: the safety of omalizumab treatment in pregnant patients with asthma". (2021), 2516-2523. https://doi.org/10.3906/sag-2101-341
APA Gemicioglu B, YALÇIN A, HAVLUCU Y, KARAKAYA G, Özdemir L, KEREN M, Bavbek S, Ediger D, Oguzulgen I, OZSEKER Z, yorgancıoglu a (2021). Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. Turkish Journal of Medical Sciences, 51(5), 2516 - 2523. 10.3906/sag-2101-341
Chicago Gemicioglu Bilun,YALÇIN Arzu Didem,HAVLUCU YAVUZ,KARAKAYA GÜL,Özdemir Levent,KEREN METİN,Bavbek Sevim,Ediger Dane,Oguzulgen I.Kivilcim,OZSEKER ZEYNEP FERHAN,yorgancıoglu arzu Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. Turkish Journal of Medical Sciences 51, no.5 (2021): 2516 - 2523. 10.3906/sag-2101-341
MLA Gemicioglu Bilun,YALÇIN Arzu Didem,HAVLUCU YAVUZ,KARAKAYA GÜL,Özdemir Levent,KEREN METİN,Bavbek Sevim,Ediger Dane,Oguzulgen I.Kivilcim,OZSEKER ZEYNEP FERHAN,yorgancıoglu arzu Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. Turkish Journal of Medical Sciences, vol.51, no.5, 2021, ss.2516 - 2523. 10.3906/sag-2101-341
AMA Gemicioglu B,YALÇIN A,HAVLUCU Y,KARAKAYA G,Özdemir L,KEREN M,Bavbek S,Ediger D,Oguzulgen I,OZSEKER Z,yorgancıoglu a Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. Turkish Journal of Medical Sciences. 2021; 51(5): 2516 - 2523. 10.3906/sag-2101-341
Vancouver Gemicioglu B,YALÇIN A,HAVLUCU Y,KARAKAYA G,Özdemir L,KEREN M,Bavbek S,Ediger D,Oguzulgen I,OZSEKER Z,yorgancıoglu a Country-based report: the safety of omalizumab treatment in pregnant patients with asthma. Turkish Journal of Medical Sciences. 2021; 51(5): 2516 - 2523. 10.3906/sag-2101-341
IEEE Gemicioglu B,YALÇIN A,HAVLUCU Y,KARAKAYA G,Özdemir L,KEREN M,Bavbek S,Ediger D,Oguzulgen I,OZSEKER Z,yorgancıoglu a "Country-based report: the safety of omalizumab treatment in pregnant patients with asthma." Turkish Journal of Medical Sciences, 51, ss.2516 - 2523, 2021. 10.3906/sag-2101-341
ISNAD Gemicioglu, Bilun vd. "Country-based report: the safety of omalizumab treatment in pregnant patients with asthma". Turkish Journal of Medical Sciences 51/5 (2021), 2516-2523. https://doi.org/10.3906/sag-2101-341
Sayfa Oluşturulma Tarihi
17-04-2024 22:51

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları